NCT06725498View on ClinicalTrials.gov

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2029

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Tislelizumab-jsgr

200mg, Q3W

DRUG

Cisplatin

60-75 mg/㎡, Q3W

DRUG

Albumin-Bound Paclitaxel

260 mg/㎡, Q3W

RADIATION

Radiotherapy

Radical Radiotherapy or adjuvant Radiotherapy per guidelines.

Trial Locations (1)

10000

RECRUITING

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER